BioRestorative Therapies Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIORESTORATIVE THERAPIES, INC. | ||
| Dated: March 29, 2024 | By: | /s/ Lance Alstodt |
|---|---|---|
| Lance Alstodt | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Capacity | Date |
|---|---|---|
| /s/ Lance Alstodt | Chief Executive Officer, President, Chairman of the Board and Director | March 29, 2024 |
| Lance Alstodt | (Principal Executive Officer) | |
| /s/ Francisco Silva | Vice President, Research and Development and Director | March 29, 2024 |
| Francisco Silva | ||
| /s/ Robert E. Kristal | Chief Financial Officer | March 29, 2024 |
| Robert E. Kristal | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Nickolay Kukekov | Director | March 29, 2024 |
| Nickolay Kukekov | ||
| /s/ Patrick F. Williams | Director | March 29, 2024 |
| Patrick F. Williams | ||
| /s/ David Rosa | Director | March 29, 2024 |
| David Rosa | ||
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 688) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Stockholders’ Equity as of December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.